SARS-CoV-2 IgM/IgG化学发光免疫分析的分析性能与抗体动力学
该研究按CLSI EP15-A3方案评估MAGLUMI 2000 Plus检测SARS-CoV-2 IgM/IgG的精密度与稀释回收,并连续采集新冠阳性患者血清观察抗体动力学。结果显示不精密度与回收可接受,IgM和IgG在症状出现6-7天后快速升高,IgG在第12天灵敏度达100%,IgM为88%。
要点
- MAGLUMI 2000 Plus检测SARS-CoV-2 IgM/IgG的精密度与稀释回收符合分析要求。
- IgM和IgG在症状出现6-7天后快速升高。
- IgG在症状出现后第12天灵敏度100%,IgM为88%。
核心结论
- MAGLUMI 2000 Plus CLIA检测COVID-19患者血清特异性IgM和IgG有效,并可获得两种抗体动力学数据。
研究设计与样本
- 采用CLSI EP15-A3方案评估MAGLUMI 2000 Plus 2019-nCov IgM和IgG检测的不精密度。
- 用高浓度池与低浓度池血清样本混合物评估稀释线性和回收率。
- 连续采集COVID-19阳性患者不同时间(<5天至26-30天)的系列血清评估免疫球蛋白时间动力学。
主要发现
- 重复性IgM<4%、IgG<6%,中间不精密度<6%。
- 稀释与回收研究结果满意。
- IgM和IgG在症状出现6-7天后快速升高。
- IgG在症状出现后第12天灵敏度100%,IgM同期最高阳性率88%。
关键数值与推荐
- 重复性:IgM<4%,IgG<6%;中间不精密度<6%。
- IgG在症状出现后第12天灵敏度100%。
- IgM在症状出现后第12天最高阳性率88%。
临床怎么用
- 可将MAGLUMI 2000 Plus CLIA用于COVID-19患者血清特异性IgM和IgG检测。
- 可利用抗体动力学数据辅助COVID-19诊断与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Coronavirus disease 2019, abbreviated to COVID-19, represents an emerging health threat worldwide as, after initial reports in China, it has continued to spread rapidly. The clinical spectrum of the disease varies from mild to severe acute respiratory distress syndrome (ARDS). Moreover, many patients can be asymptomatic, thus increasing the uncertainty of the diagnostic work-up. Laboratory tests play a pivotal role in the diagnosis and management of COVID-19, the current gold standard being real-time reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens. However, the diagnostic accuracy of rRT-PCR depends on many pre-analytical and analytical variables. The measurement of specific COVID-19 antibodies (both IgG and IgM) should serve as an additional, non-invasive tool for disease detection and management. Methods The imprecision of the MAGLUMI™ 2000 Plus 2019-nCov IgM and IgG assays (Snibe, Shenzhen, China) was assessed by adopting the Clinical and Laboratory Standards Institute (CLSI) EP15-A3 protocol. Linearity of dilution and recovery was evaluated by means of mixes of high-level pools and low-level pools of serum samples. Immunoglobulin time kinetics were evaluated using a series of serum samples, repeatedly collected from COVID-19-positive patients at different times, from <5 days up to 26-30 days. Results Findings at the analytical validation of the assay carried out according to the CLSI EP15-A3 guideline demonstrated that imprecision and repeatability were acceptable (repeatability was <4% and <6% for IgM and IgG, respectively, whilst intermediate imprecision was <6%). In addition, results of dilution and recovery studies were satisfactory. The kinetics of COVID-19 antibodies confirmed previously reported findings, showing a rapid increase of both IgM and IgG after 6-7 days from the symptom onset. IgG had 100% sensitivity on day 12, whilst 88% was the higher positive rate achieved for IgM after the same time interval. Conclusions The findings of this study demonstrate the validity of the MAGLUMI 2000 Plus CLIA assay for the measurement of specific IgM and IgG in sera of COVID-19 patients, and for obtaining valuable data on the kinetics of both (IgM and IgG) COVID-19 antibodies. These data represent a pre-requisite for the appropriate utilization of specific antibodies for the diagnosis and management of COVID-19 patients.
引用
- Padoan A, Cosma C, Sciacovelli L, et al. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med. 2020. PMID: 32301749. doi:10.1515/cclm-2020-0443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。